# Clinical Intelligence Platform
## H-34 DELTA Revision Cup Study - POC Design

**Version:** 9.0 | **Date:** January 11, 2026 | **POC Demonstration-Ready Agentic Intelligence Platform**

---

## Executive Summary: Why This Wins

> **This is not a chatbot on a spreadsheet.** This is an **Agentic AI-driven Clinical Intelligence Platform** that transforms how medical device studies are monitored, analyzed, and reported.

### The Problem We Solve

Clinical teams spend **days or weeks** manually:
- Cross-referencing protocol PDFs with Excel exports
- Searching literature for benchmark comparisons
- Compiling regulatory-ready evidence packages
- Identifying patients who need attention

### What We Deliver

| Traditional Approach | Our Platform |
|---------------------|--------------|
| Query one data source at a time | **Multi-source reasoning** across 8 source types |
| Manually read protocol PDF | **Document-as-Code** executes protocol rules automatically |
| Hours to compile status report | **30-second executive briefings** with full provenance |
| Reactiveâ€”find problems after they occur | **Proactive alerts** detect signals before they escalate |
| Data only | **Actionable intelligence** with specific recommendations |

### Five Capabilities No One Else Can Deliver

1. **Regulatory Readiness in 30 Seconds** â€” Gap analysis across protocol + data + literature + registry
2. **Safety Signals with Context** â€” Not just "rate is high" but "here's why, here's what to do"
3. **Protocol Deviations Detected Automatically** â€” Document-as-Code validates every patient, every visit
4. **Risk-Stratified Patient Lists** â€” ML + literature-grounded scoring with explainable factors
5. **Executive Intelligence Dashboard** â€” One view aggregating 6+ sources into strategic priorities

---

# PART 1: WHAT WE WILL DEMONSTRATE

---

## TOP 5 POC USE CASES

> **Selection Criteria:** These 5 use cases were selected to demonstrate capabilities that (1) CANNOT be achieved with traditional BI or simple chatbots, (2) require multi-source reasoning across structured + unstructured data, (3) leverage Document-as-Code for executable intelligence, and (4) produce concrete, actionable outputs that change clinical and operational decisions.

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚                              TOP 5 POC USE CASES AT A GLANCE                                     â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                                                                  â”‚
â”‚  UC1  REGULATORY SUBMISSION           Multi-source gap analysis producing                       â”‚
â”‚       READINESS ASSESSMENT            actionable remediation checklist                          â”‚
â”‚       â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•  â”‚
â”‚                                                                                                  â”‚
â”‚  UC2  SAFETY SIGNAL DETECTION         Cross-source signal correlation with                      â”‚
â”‚       & CONTEXTUALIZATION             literature-grounded risk interpretation                   â”‚
â”‚       â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•  â”‚
â”‚                                                                                                  â”‚
â”‚  UC3  AUTOMATED PROTOCOL              Document-as-Code execution detecting                      â”‚
â”‚       DEVIATION DETECTION             and classifying deviations in real-time                   â”‚
â”‚       â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•  â”‚
â”‚                                                                                                  â”‚
â”‚  UC4  PATIENT RISK STRATIFICATION     ML + Literature + Registry producing                      â”‚
â”‚       WITH ACTIONABLE MONITORING      prioritized surveillance lists                            â”‚
â”‚       â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•  â”‚
â”‚                                                                                                  â”‚
â”‚  UC5  INTELLIGENT STUDY HEALTH        Aggregated multi-source intelligence                      â”‚
â”‚       EXECUTIVE DASHBOARD             with strategic decision support                           â”‚
â”‚       â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•  â”‚
â”‚                                                                                                  â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

---

### UC1: Regulatory Submission Readiness Assessment

> **The Business Problem:** Clinical teams spend weeks manually cross-referencing protocol requirements, study data, literature benchmarks, and regulatory expectations to assess submission readiness. Gaps are discovered late, causing delays.

**What Traditional Tools Do:** Generate data listings; user manually compares to protocol PDF.

**What Our Platform Does:**

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚  USE CASE 1: REGULATORY SUBMISSION READINESS ASSESSMENT                                          â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                                                                  â”‚
â”‚  USER QUERY: "Are we ready to submit? What gaps need to be addressed?"                          â”‚
â”‚                                                                                                  â”‚
â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”   â”‚
â”‚  â”‚ AGENT ORCHESTRATION (executes in <30 seconds)                                           â”‚   â”‚
â”‚  â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤   â”‚
â”‚  â”‚                                                                                          â”‚   â”‚
â”‚  â”‚  1. PROTOCOL AGENT: Load protocol_rules.yaml â†’ Extract submission requirements          â”‚   â”‚
â”‚  â”‚     â€¢ Primary endpoint: HHS improvement â‰¥20 points at 2 years                           â”‚   â”‚
â”‚  â”‚     â€¢ Sample size: nâ‰¥25 evaluable for interim, n=50 for final                          â”‚   â”‚
â”‚  â”‚     â€¢ Safety: Complete AE documentation, SAE narratives                                 â”‚   â”‚
â”‚  â”‚     â€¢ Radiographic: All timepoint imaging reviewed                                      â”‚   â”‚
â”‚  â”‚                                                                                          â”‚   â”‚
â”‚  â”‚  2. DATA AGENT: Query H-34 study data â†’ Calculate current status                        â”‚   â”‚
â”‚  â”‚     â€¢ Primary endpoint: 5/8 achieved MCID (62%), n=8 evaluable                         â”‚   â”‚
â”‚  â”‚     â€¢ Safety: 15 AEs documented, 12 SAEs with narratives                               â”‚   â”‚
â”‚  â”‚     â€¢ Radiographic: 3 patients missing 1yr imaging                                      â”‚   â”‚
â”‚  â”‚                                                                                          â”‚   â”‚
â”‚  â”‚  3. LITERATURE AGENT: Load literature_benchmarks.yaml â†’ Retrieve comparators            â”‚   â”‚
â”‚  â”‚     â€¢ Meding et al: 72% MCID (our 62% within range)                                    â”‚   â”‚
â”‚  â”‚     â€¢ Revision rate benchmark: 6.2% (our 8.1% at upper boundary)                        â”‚   â”‚
â”‚  â”‚                                                                                          â”‚   â”‚
â”‚  â”‚  4. REGISTRY AGENT: Load registry_norms.yaml â†’ External validation                      â”‚   â”‚
â”‚  â”‚     â€¢ AOANJRR 2yr survival: 94% (our ~92% within CI)                                   â”‚   â”‚
â”‚  â”‚                                                                                          â”‚   â”‚
â”‚  â”‚  5. COMPLIANCE AGENT: Cross-reference all sources â†’ Gap analysis                        â”‚   â”‚
â”‚  â”‚                                                                                          â”‚   â”‚
â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜   â”‚
â”‚                                                                                                  â”‚
â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”   â”‚
â”‚  â”‚ OUTPUT: SUBMISSION READINESS REPORT                                                      â”‚   â”‚
â”‚  â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤   â”‚
â”‚  â”‚                                                                                          â”‚   â”‚
â”‚  â”‚  OVERALL READINESS: 72% â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–‘â–‘â–‘â–‘â–‘â–‘â–‘â–‘ (Target: 90% for submission)           â”‚   â”‚
â”‚  â”‚                                                                                          â”‚   â”‚
â”‚  â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”   â”‚   â”‚
â”‚  â”‚  â”‚ CATEGORY               STATUS    FINDING                      ACTION REQUIRED   â”‚   â”‚   â”‚
â”‚  â”‚  â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤   â”‚   â”‚
â”‚  â”‚  â”‚ Primary Endpoint       âœ… PASS   62% MCID (â‰¥50% required)     None              â”‚   â”‚   â”‚
â”‚  â”‚  â”‚ Sample Size            ğŸ”´ GAP    8/25 evaluable (32%)         Chase 17 patients â”‚   â”‚   â”‚
â”‚  â”‚  â”‚ Literature Benchmark   âœ… PASS   Within published ranges      None              â”‚   â”‚   â”‚
â”‚  â”‚  â”‚ Registry Comparison    âš ï¸ WATCH  Revision rate at 95th %ile   Add narrative     â”‚   â”‚   â”‚
â”‚  â”‚  â”‚ Safety Documentation   âœ… PASS   All SAEs have narratives     None              â”‚   â”‚   â”‚
â”‚  â”‚  â”‚ Radiographic Data      ğŸ”´ GAP    3 patients missing 1yr       Chase list below  â”‚   â”‚   â”‚
â”‚  â”‚  â”‚ Protocol Deviations    âš ï¸ WATCH  4 timing deviations          Document in CSR   â”‚   â”‚   â”‚
â”‚  â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜   â”‚   â”‚
â”‚  â”‚                                                                                          â”‚   â”‚
â”‚  â”‚  BLOCKERS (Must resolve before submission):                                              â”‚   â”‚
â”‚  â”‚  1. Sample size: 17 additional patients need 2-year follow-up                           â”‚   â”‚
â”‚  â”‚  2. Radiographic gaps: Patients 12, 19, 27 missing 1-year imaging                       â”‚   â”‚
â”‚  â”‚                                                                                          â”‚   â”‚
â”‚  â”‚  WARNINGS (Should address, not blocking):                                                â”‚   â”‚
â”‚  â”‚  1. Revision rate narrative: Explain 8.1% vs registry 6.2% (early failure cluster)      â”‚   â”‚
â”‚  â”‚  2. Protocol deviations: Document 4 timing deviations in CSR                            â”‚   â”‚
â”‚  â”‚                                                                                          â”‚   â”‚
â”‚  â”‚  PROJECTED READINESS TIMELINE:                                                           â”‚   â”‚
â”‚  â”‚  â€¢ Current: 72% ready                                                                    â”‚   â”‚
â”‚  â”‚  â€¢ +30 days (chase radiographic): 78% ready                                             â”‚   â”‚
â”‚  â”‚  â€¢ +90 days (additional 2yr FU): 85% ready                                              â”‚   â”‚
â”‚  â”‚  â€¢ +180 days (target n=25): 92% ready âœ… SUBMISSION VIABLE                              â”‚   â”‚
â”‚  â”‚                                                                                          â”‚   â”‚
â”‚  â”‚  [Download Checklist PDF] [Generate Chase List] [Draft CSR Section] [Email to Team]     â”‚   â”‚
â”‚  â”‚                                                                                          â”‚   â”‚
â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜   â”‚
â”‚                                                                                                  â”‚
â”‚  PROVENANCE: Protocol (CIP v2.0 Sections 8, 10), Study Data (Sheets 1, 17, 18, 20),            â”‚
â”‚  Literature (Meding 2025, Vasios et al), Registry (AOANJRR 2024)                               â”‚
â”‚                                                                                                  â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

| Aspect | Why This Wins |
|--------|---------------|
| **Multi-Source** | Combines Protocol + Study Data + Literature + Registry in single analysis |
| **Document-as-Code** | Protocol requirements are executable rules, not text to read |
| **Actionable** | Produces specific blockers, chase lists, and timeline projections |
| **Differentiating** | No traditional BI tool can do this; would take analyst days manually |

---

### UC2: Safety Signal Detection & Contextualization

> **The Business Problem:** Safety signals in small studies are hard to interpret without external context. Is a 13% fracture rate concerning? Teams manually search literature and registries for benchmarks.

**What Traditional Tools Do:** Count AEs; user manually researches if rates are normal.

**What Our Platform Does:**

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚  USE CASE 2: SAFETY SIGNAL DETECTION & CONTEXTUALIZATION                                         â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                                                                  â”‚
â”‚  PROACTIVE ALERT (System-Generated, No User Query Required):                                    â”‚
â”‚                                                                                                  â”‚
â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”   â”‚
â”‚  â”‚ ğŸš¨ SAFETY SIGNAL DETECTED: Periprosthetic Fracture Rate Exceeds Benchmarks               â”‚   â”‚
â”‚  â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤   â”‚
â”‚  â”‚                                                                                          â”‚   â”‚
â”‚  â”‚  SIGNAL IDENTIFICATION:                                                                  â”‚   â”‚
â”‚  â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”  â”‚   â”‚
â”‚  â”‚  â”‚ Metric              H-34 Study    Literature      Registry       Status           â”‚  â”‚   â”‚
â”‚  â”‚  â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤  â”‚   â”‚
â”‚  â”‚  â”‚ Fracture Rate       13% (5/37)    4-8%            <10%           ğŸ”´ ELEVATED      â”‚  â”‚   â”‚
â”‚  â”‚  â”‚ Dislocation Rate    5% (2/37)     3-6%            5%             âœ… NORMAL        â”‚  â”‚   â”‚
â”‚  â”‚  â”‚ Infection Rate      3% (1/37)     2-4%            3%             âœ… NORMAL        â”‚  â”‚   â”‚
â”‚  â”‚  â”‚ Overall AE Rate     35% (13/37)   28-40%          35%            âœ… NORMAL        â”‚  â”‚   â”‚
â”‚  â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜  â”‚   â”‚
â”‚  â”‚                                                                                          â”‚   â”‚
â”‚  â”‚  CROSS-SOURCE CONTEXTUALIZATION:                                                         â”‚   â”‚
â”‚  â”‚                                                                                          â”‚   â”‚
â”‚  â”‚  ğŸ“Š Study Data Analysis:                                                                 â”‚   â”‚
â”‚  â”‚     â€¢ 5 periprosthetic fractures in 37 patients (13%)                                   â”‚   â”‚
â”‚  â”‚     â€¢ Timing: 4/5 occurred within 90 days (intraop or early postop)                     â”‚   â”‚
â”‚  â”‚     â€¢ Pattern: 100% (5/5) occurred in patients with osteoporosis diagnosis              â”‚   â”‚
â”‚  â”‚                                                                                          â”‚   â”‚
â”‚  â”‚  ğŸ“š Literature Correlation (Dixon et al 2025, Harris et al 2025):                        â”‚   â”‚
â”‚  â”‚     â€¢ Osteoporosis identified as primary risk factor for periprosthetic fracture        â”‚   â”‚
â”‚  â”‚     â€¢ Expected rate in osteoporotic patients: 15-20% (vs 4% in non-osteoporotic)       â”‚   â”‚
â”‚  â”‚     â€¢ H-34 osteoporosis prevalence: 32% (12/37)â€”higher than typical study population   â”‚   â”‚
â”‚  â”‚                                                                                          â”‚   â”‚
â”‚  â”‚  ğŸ“ˆ Registry Context (AOANJRR 2024):                                                     â”‚   â”‚
â”‚  â”‚     â€¢ Overall fracture rate threshold for concern: >10%                                 â”‚   â”‚
â”‚  â”‚     â€¢ Risk-adjusted expectation for high-osteoporosis cohort: 10-15%                   â”‚   â”‚
â”‚  â”‚     â€¢ H-34 rate (13%) is WITHIN risk-adjusted expectation                              â”‚   â”‚
â”‚  â”‚                                                                                          â”‚   â”‚
â”‚  â”‚  ğŸ“„ Protocol Check (CIP v2.0 Section 5.2):                                               â”‚   â”‚
â”‚  â”‚     â€¢ Osteoporosis is NOT an exclusion criterion                                        â”‚   â”‚
â”‚  â”‚     â€¢ No enhanced monitoring protocol specified for bone quality                         â”‚   â”‚
â”‚  â”‚                                                                                          â”‚   â”‚
â”‚  â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”  â”‚   â”‚
â”‚  â”‚  â”‚ SIGNAL INTERPRETATION                                                              â”‚  â”‚   â”‚
â”‚  â”‚  â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤  â”‚   â”‚
â”‚  â”‚  â”‚                                                                                    â”‚  â”‚   â”‚
â”‚  â”‚  â”‚ CONFIDENCE: HIGH (3 corroborating sources)                                        â”‚  â”‚   â”‚
â”‚  â”‚  â”‚                                                                                    â”‚  â”‚   â”‚
â”‚  â”‚  â”‚ CONCLUSION: Elevated fracture rate is EXPLAINED by patient population             â”‚  â”‚   â”‚
â”‚  â”‚  â”‚ characteristics (high osteoporosis prevalence), NOT implant failure.              â”‚  â”‚   â”‚
â”‚  â”‚  â”‚ Rate is within literature-predicted range for this risk profile.                  â”‚  â”‚   â”‚
â”‚  â”‚  â”‚                                                                                    â”‚  â”‚   â”‚
â”‚  â”‚  â”‚ REGULATORY IMPLICATION: Signal requires documentation but does not indicate       â”‚  â”‚   â”‚
â”‚  â”‚  â”‚ device defect. Recommend enhanced labeling for osteoporotic patients.             â”‚  â”‚   â”‚
â”‚  â”‚  â”‚                                                                                    â”‚  â”‚   â”‚
â”‚  â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜  â”‚   â”‚
â”‚  â”‚                                                                                          â”‚   â”‚
â”‚  â”‚  RECOMMENDED ACTIONS:                                                                    â”‚   â”‚
â”‚  â”‚  1. [Generate Safety Narrative] for regulatory submission                               â”‚   â”‚
â”‚  â”‚  2. [Draft Protocol Amendment] for enhanced bone density screening                      â”‚   â”‚
â”‚  â”‚  3. [Create IFU Update] with osteoporosis precaution language                          â”‚   â”‚
â”‚  â”‚  4. [Flag Similar Patients] (7 remaining with osteoporosis) for enhanced monitoring    â”‚   â”‚
â”‚  â”‚                                                                                          â”‚   â”‚
â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜   â”‚
â”‚                                                                                                  â”‚
â”‚  PROVENANCE: Study AEs (Sheet 17), Patient diagnoses (Sheet 2), Literature (Dixon 2025,        â”‚
â”‚  Harris 2025), Registry (AOANJRR 2024 Section 4.3), Protocol (CIP v2.0 Section 5.2)           â”‚
â”‚                                                                                                  â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

| Aspect | Why This Wins |
|--------|---------------|
| **Proactive** | System detects and alerts without user query |
| **Multi-Source** | Correlates AE data + patient characteristics + literature + registry + protocol |
| **Contextualized** | Doesn't just flag "high rate"â€”explains WHY and if it's expected |
| **Actionable** | Specific regulatory and clinical recommendations with one-click generation |

---

### UC3: Automated Protocol Deviation Detection & Classification

> **The Business Problem:** Protocol deviations are identified manually by comparing visit dates to protocol windowsâ€”tedious, error-prone, and often discovered late during monitoring visits.

**What Traditional Tools Do:** List visit dates; user manually checks against protocol PDF.

**What Our Platform Does:**

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚  USE CASE 3: AUTOMATED PROTOCOL DEVIATION DETECTION & CLASSIFICATION                             â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                                                                  â”‚
â”‚  DOCUMENT-AS-CODE EXECUTION (Runs automatically on data refresh):                               â”‚
â”‚                                                                                                  â”‚
â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”   â”‚
â”‚  â”‚ PROTOCOL RULES LOADED: protocol_rules.yaml                                               â”‚   â”‚
â”‚  â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤   â”‚
â”‚  â”‚                                                                                          â”‚   â”‚
â”‚  â”‚  Visit Windows (from CIP v2.0 Section 6.2):                                             â”‚   â”‚
â”‚  â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”   â”‚   â”‚
â”‚  â”‚  â”‚ Visit        Target Day    Window         Required Assessments                   â”‚   â”‚   â”‚
â”‚  â”‚  â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤   â”‚   â”‚
â”‚  â”‚  â”‚ 2-Month      Day 60        [-14, +28]     HHS, OHS, Radiology, AE Review        â”‚   â”‚   â”‚
â”‚  â”‚  â”‚ 6-Month      Day 180       [-30, +30]     HHS, OHS, Radiology, AE Review        â”‚   â”‚   â”‚
â”‚  â”‚  â”‚ 1-Year       Day 365       [-30, +60]     HHS, OHS, Radiology, AE Review        â”‚   â”‚   â”‚
â”‚  â”‚  â”‚ 2-Year       Day 730       [-60, +60]     HHS, OHS, Radiology, AE Review        â”‚   â”‚   â”‚
â”‚  â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜   â”‚   â”‚
â”‚  â”‚                                                                                          â”‚   â”‚
â”‚  â”‚  Deviation Classification (from CIP v2.0 Section 7.2):                                  â”‚   â”‚
â”‚  â”‚  â€¢ MINOR: Within 1.5x window extension                                                  â”‚   â”‚
â”‚  â”‚  â€¢ MAJOR: Beyond 1.5x window OR missing critical assessment                            â”‚   â”‚
â”‚  â”‚  â€¢ CRITICAL: Affects primary endpoint evaluability                                      â”‚   â”‚
â”‚  â”‚                                                                                          â”‚   â”‚
â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜   â”‚
â”‚                                                                                                  â”‚
â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”   â”‚
â”‚  â”‚ EXECUTION: FOR EACH patient, FOR EACH visit â†’ Validate against rules                    â”‚   â”‚
â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜   â”‚
â”‚                                                                                                  â”‚
â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”   â”‚
â”‚  â”‚ OUTPUT: PROTOCOL DEVIATION REPORT                                                        â”‚   â”‚
â”‚  â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤   â”‚
â”‚  â”‚                                                                                          â”‚   â”‚
â”‚  â”‚  SUMMARY: 37 patients Ã— 4 visits = 148 visit-assessments evaluated                      â”‚   â”‚
â”‚  â”‚           6 deviations detected (4.1% deviation rate)                                   â”‚   â”‚
â”‚  â”‚                                                                                          â”‚   â”‚
â”‚  â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”   â”‚   â”‚
â”‚  â”‚  â”‚ DEVIATION DETAIL                                                                 â”‚   â”‚   â”‚
â”‚  â”‚  â”œâ”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤   â”‚   â”‚
â”‚  â”‚  â”‚ Pat   â”‚ Visit  â”‚ Expected â”‚ Actual   â”‚ Delta   â”‚ Class      â”‚ Impact            â”‚   â”‚   â”‚
â”‚  â”‚  â”œâ”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤   â”‚   â”‚
â”‚  â”‚  â”‚ 15    â”‚ 6mo    â”‚ Mar 15   â”‚ Apr 22   â”‚ +38d    â”‚ MINOR      â”‚ Within tolerance  â”‚   â”‚   â”‚
â”‚  â”‚  â”‚ 22    â”‚ 1yr    â”‚ Aug 10   â”‚ Oct 25   â”‚ +76d    â”‚ MAJOR      â”‚ Outside window    â”‚   â”‚   â”‚
â”‚  â”‚  â”‚ 8     â”‚ 2mo    â”‚ Nov 20   â”‚ Dec 28   â”‚ +38d    â”‚ MINOR      â”‚ Within tolerance  â”‚   â”‚   â”‚
â”‚  â”‚  â”‚ 19    â”‚ 1yr    â”‚ Jun 05   â”‚ MISSING  â”‚ N/A     â”‚ MAJOR      â”‚ Assessment gap    â”‚   â”‚   â”‚
â”‚  â”‚  â”‚ 12    â”‚ 1yr    â”‚ Jul 18   â”‚ Jul 18   â”‚ 0d      â”‚ â€”          â”‚ Radiology MISSING â”‚   â”‚   â”‚
â”‚  â”‚  â”‚ 27    â”‚ 6mo    â”‚ Feb 28   â”‚ Mar 15   â”‚ +15d    â”‚ MINOR      â”‚ Within tolerance  â”‚   â”‚   â”‚
â”‚  â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜   â”‚   â”‚
â”‚  â”‚                                                                                          â”‚   â”‚
â”‚  â”‚  DEVIATION BREAKDOWN:                                                                    â”‚   â”‚
â”‚  â”‚  â€¢ MINOR: 3 (timing within extended windowâ€”document only)                               â”‚   â”‚
â”‚  â”‚  â€¢ MAJOR: 2 (outside window or missing visitâ€”requires explanation)                      â”‚   â”‚
â”‚  â”‚  â€¢ CRITICAL: 1 (Patient 12 missing radiology affects endpoint)                          â”‚   â”‚
â”‚  â”‚                                                                                          â”‚   â”‚
â”‚  â”‚  AUTOMATED OUTPUTS GENERATED:                                                            â”‚   â”‚
â”‚  â”‚  âœ… PD Log entries pre-populated (requires PI signature)                                â”‚   â”‚
â”‚  â”‚  âœ… Site query forms generated for MAJOR/CRITICAL deviations                            â”‚   â”‚
â”‚  â”‚  âœ… CSR deviation table updated                                                          â”‚   â”‚
â”‚  â”‚  âœ… Monitoring visit agenda updated with deviation review items                          â”‚   â”‚
â”‚  â”‚                                                                                          â”‚   â”‚
â”‚  â”‚  [Download PD Log] [Send Site Queries] [Update CSR] [View Trends by Visit Type]         â”‚   â”‚
â”‚  â”‚                                                                                          â”‚   â”‚
â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜   â”‚
â”‚                                                                                                  â”‚
â”‚  PROVENANCE: Protocol rules (CIP v2.0 Sections 6.2, 7.2), Surgery dates (Sheet 4),             â”‚
â”‚  Visit dates (Sheets 7-16), Assessment completion (all follow-up sheets)                       â”‚
â”‚                                                                                                  â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

| Aspect | Why This Wins |
|--------|---------------|
| **Document-as-Code** | Protocol windows are executable rules, not text to interpret |
| **Automated** | Runs on every data refreshâ€”deviations caught in real-time, not at monitoring visits |
| **Classified** | System applies protocol-defined severity categories automatically |
| **Integrated** | Outputs feed directly into PD logs, site queries, CSRâ€”no manual transcription |

---

### UC4: Patient Risk Stratification with Actionable Monitoring Lists

> **The Business Problem:** Which patients need enhanced monitoring? Without predictive tools, all patients get the same attention, wasting resources on low-risk patients while missing early warning signs in high-risk patients.

**What Traditional Tools Do:** List all patients; user subjectively prioritizes.

**What Our Platform Does:**

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚  USE CASE 4: PATIENT RISK STRATIFICATION WITH ACTIONABLE MONITORING LISTS                        â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                                                                  â”‚
â”‚  USER QUERY: "Which patients should I be most concerned about?"                                 â”‚
â”‚                                                                                                  â”‚
â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”   â”‚
â”‚  â”‚ MULTI-MODEL RISK SCORING                                                                 â”‚   â”‚
â”‚  â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤   â”‚
â”‚  â”‚                                                                                          â”‚   â”‚
â”‚  â”‚  Model 1: ML Revision Risk (XGBoost, trained on 737 patients)                           â”‚   â”‚
â”‚  â”‚  Model 2: Literature Risk Factors (Dixon et al, Harris et al hazard ratios)             â”‚   â”‚
â”‚  â”‚  Model 3: Registry Benchmarks (AOANJRR risk-adjusted expectations)                      â”‚   â”‚
â”‚  â”‚  Model 4: Protocol Compliance (deviation accumulation score)                            â”‚   â”‚
â”‚  â”‚                                                                                          â”‚   â”‚
â”‚  â”‚  Combined Score = Weighted ensemble with uncertainty quantification                      â”‚   â”‚
â”‚  â”‚                                                                                          â”‚   â”‚
â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜   â”‚
â”‚                                                                                                  â”‚
â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”   â”‚
â”‚  â”‚ OUTPUT: PRIORITIZED PATIENT MONITORING LIST                                              â”‚   â”‚
â”‚  â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤   â”‚
â”‚  â”‚                                                                                          â”‚   â”‚
â”‚  â”‚  ğŸ”´ HIGH PRIORITY (Enhanced Surveillance Required) â€” 4 patients                         â”‚   â”‚
â”‚  â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”   â”‚   â”‚
â”‚  â”‚  â”‚ Patient â”‚ Risk   â”‚ Key Factors                         â”‚ Recommended Action     â”‚   â”‚   â”‚
â”‚  â”‚  â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤   â”‚   â”‚
â”‚  â”‚  â”‚ 19      â”‚ 28%    â”‚ BMI 36 + Osteoporosis + Zone 2      â”‚ Urgent radiology reviewâ”‚   â”‚   â”‚
â”‚  â”‚  â”‚         â”‚        â”‚ lucency at 6mo + slow HHS recovery  â”‚ + clinical assessment  â”‚   â”‚   â”‚
â”‚  â”‚  â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤   â”‚   â”‚
â”‚  â”‚  â”‚ 8       â”‚ 24%    â”‚ HHS 'Very Poor' at 1yr (38) +       â”‚ Non-implant cause      â”‚   â”‚   â”‚
â”‚  â”‚  â”‚         â”‚        â”‚ Baseline HHS 25 + Re-revision case  â”‚ workup recommended     â”‚   â”‚   â”‚
â”‚  â”‚  â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤   â”‚   â”‚
â”‚  â”‚  â”‚ 22      â”‚ 22%    â”‚ HHS trajectory 2.1 SD below mean +  â”‚ Expedite 1yr visit     â”‚   â”‚   â”‚
â”‚  â”‚  â”‚         â”‚        â”‚ BMI 34 + Missed 1yr visit (overdue) â”‚ + retention outreach   â”‚   â”‚   â”‚
â”‚  â”‚  â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤   â”‚   â”‚
â”‚  â”‚  â”‚ 15      â”‚ 19%    â”‚ Score regression (58â†’52) + matches  â”‚ Enhanced 2yr monitoringâ”‚   â”‚   â”‚
â”‚  â”‚  â”‚         â”‚        â”‚ 'poor responder' trajectory cluster â”‚ protocol               â”‚   â”‚   â”‚
â”‚  â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜   â”‚   â”‚
â”‚  â”‚                                                                                          â”‚   â”‚
â”‚  â”‚  ğŸŸ¡ MODERATE PRIORITY (Standard Monitoring + Watch) â€” 12 patients                       â”‚   â”‚
â”‚  â”‚  â€¢ Patients with 1-2 risk factors but stable trajectories                              â”‚   â”‚
â”‚  â”‚  â€¢ [View List] [Download for Site]                                                      â”‚   â”‚
â”‚  â”‚                                                                                          â”‚   â”‚
â”‚  â”‚  ğŸŸ¢ LOW PRIORITY (Standard Protocol) â€” 21 patients                                      â”‚   â”‚
â”‚  â”‚  â€¢ On-track recovery, no elevated risk factors                                          â”‚   â”‚
â”‚  â”‚  â€¢ [View List]                                                                           â”‚   â”‚
â”‚  â”‚                                                                                          â”‚   â”‚
â”‚  â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”  â”‚   â”‚
â”‚  â”‚  â”‚ RISK FACTOR CONTRIBUTION ANALYSIS (Patient 19 Example)                            â”‚  â”‚   â”‚
â”‚  â”‚  â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤  â”‚   â”‚
â”‚  â”‚  â”‚                                                                                    â”‚  â”‚   â”‚
â”‚  â”‚  â”‚  Base risk (cohort average):                    8%  â–ˆâ–ˆâ–ˆâ–ˆ                          â”‚  â”‚   â”‚
â”‚  â”‚  â”‚  + BMI 36 (HR 1.6 per AOANJRR):               +5%  â–ˆâ–ˆ                             â”‚  â”‚   â”‚
â”‚  â”‚  â”‚  + Osteoporosis (HR 2.4 per Dixon):           +8%  â–ˆâ–ˆâ–ˆâ–ˆ                           â”‚  â”‚   â”‚
â”‚  â”‚  â”‚  + Progressive lucency (literature signal):   +4%  â–ˆâ–ˆ                             â”‚  â”‚   â”‚
â”‚  â”‚  â”‚  + Slow HHS recovery (ML trajectory):         +3%  â–ˆ                              â”‚  â”‚   â”‚
â”‚  â”‚  â”‚  â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€                            â”‚  â”‚   â”‚
â”‚  â”‚  â”‚  Total predicted risk:                        28%  â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆ                 â”‚  â”‚   â”‚
â”‚  â”‚  â”‚                                                                                    â”‚  â”‚   â”‚
â”‚  â”‚  â”‚  Confidence: 78% (validated on synthetic + real data)                             â”‚  â”‚   â”‚
â”‚  â”‚  â”‚                                                                                    â”‚  â”‚   â”‚
â”‚  â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜  â”‚   â”‚
â”‚  â”‚                                                                                          â”‚   â”‚
â”‚  â”‚  [Generate Enhanced Monitoring Protocol] [Email Site with Priority List]                â”‚   â”‚
â”‚  â”‚  [Schedule Follow-up Calls] [Export to Clinical Dashboard]                              â”‚   â”‚
â”‚  â”‚                                                                                          â”‚   â”‚
â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜   â”‚
â”‚                                                                                                  â”‚
â”‚  PROVENANCE: ML model (trained on synthetic data), Literature HRs (Dixon, Harris, Meding),     â”‚
â”‚  Registry norms (AOANJRR), Study data (Sheets 1, 2, 17, 18, radiology sheets)                 â”‚
â”‚                                                                                                  â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

| Aspect | Why This Wins |
|--------|---------------|
| **Explainable** | Shows exactly which factors contribute to each patient's risk score |
| **Literature-Grounded** | Risk factors come from published hazard ratios, not black-box ML |
| **Actionable** | Specific recommendations per patient, not just a number |
| **Prioritized** | Clinical team knows exactly where to focus limited resources |

---

### UC5: Intelligent Study Health Executive Dashboard

> **The Business Problem:** Executives need a single view of study status, but information is scattered across data exports, protocol documents, safety databases, and regulatory trackers. Preparing a status update takes days.

**What Traditional Tools Do:** Multiple reports that don't talk to each other; manual synthesis required.

**What Our Platform Does:**

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚  USE CASE 5: INTELLIGENT STUDY HEALTH EXECUTIVE DASHBOARD                                        â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                                                                  â”‚
â”‚  REAL-TIME AGGREGATED INTELLIGENCE (Updates automatically on data refresh)                      â”‚
â”‚                                                                                                  â”‚
â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”   â”‚
â”‚  â”‚                                                                                          â”‚   â”‚
â”‚  â”‚   H-34 DELTA REVISION CUP STUDY â€” EXECUTIVE INTELLIGENCE BRIEFING                       â”‚   â”‚
â”‚  â”‚   Generated: January 11, 2026 14:32 UTC | Data as of: January 10, 2026                  â”‚   â”‚
â”‚  â”‚                                                                                          â”‚   â”‚
â”‚  â”‚  â•”â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•— â”‚   â”‚
â”‚  â”‚  â•‘                                                                                    â•‘ â”‚   â”‚
â”‚  â”‚  â•‘   OVERALL STUDY HEALTH:  72/100  â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–‘â–‘â–‘â–‘â–‘â–‘  GOOD (Target: 80)         â•‘ â”‚   â”‚
â”‚  â”‚  â•‘                                                                                    â•‘ â”‚   â”‚
â”‚  â”‚  â• â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•£ â”‚   â”‚
â”‚  â”‚  â•‘                                                                                    â•‘ â”‚   â”‚
â”‚  â”‚  â•‘   ğŸ“Š ENROLLMENT        37/50  â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–‘â–‘â–‘â–‘  74%  On Track               â•‘ â”‚   â”‚
â”‚  â”‚  â•‘   ğŸ¯ EFFICACY          62%    â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–‘â–‘â–‘â–‘â–‘â–‘â–‘  MCID Achieved (n=8)          â•‘ â”‚   â”‚
â”‚  â”‚  â•‘   âš ï¸ SAFETY            35%    AE rate within range; fracture signal monitored    â•‘ â”‚   â”‚
â”‚  â”‚  â•‘   ğŸ“‹ COMPLIANCE        96%    2 minor deviations; 100% SAE reporting             â•‘ â”‚   â”‚
â”‚  â”‚  â•‘   ğŸ“ DATA QUALITY      87%    23 queries open; 3 critical                        â•‘ â”‚   â”‚
â”‚  â”‚  â•‘                                                                                    â•‘ â”‚   â”‚
â”‚  â”‚  â•šâ•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â• â”‚   â”‚
â”‚  â”‚                                                                                          â”‚   â”‚
â”‚  â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”   â”‚   â”‚
â”‚  â”‚  â”‚ ğŸš¨ ATTENTION REQUIRED (Aggregated from all sources)                              â”‚   â”‚   â”‚
â”‚  â”‚  â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤   â”‚   â”‚
â”‚  â”‚  â”‚                                                                                  â”‚   â”‚   â”‚
â”‚  â”‚  â”‚ 1. ğŸ”´ SAMPLE SIZE GAP: Only 8/25 patients at 2-year endpoint (32%)              â”‚   â”‚   â”‚
â”‚  â”‚  â”‚    Source: Study Data + Protocol requirement                                     â”‚   â”‚   â”‚
â”‚  â”‚  â”‚    Impact: Interim analysis delayed until Q3 2026                               â”‚   â”‚   â”‚
â”‚  â”‚  â”‚    Action: [View Retention Plan] [Project Timeline]                             â”‚   â”‚   â”‚
â”‚  â”‚  â”‚                                                                                  â”‚   â”‚   â”‚
â”‚  â”‚  â”‚ 2. ğŸŸ¡ FRACTURE SIGNAL: 13% rate (literature: 4-8%, but explained by population) â”‚   â”‚   â”‚
â”‚  â”‚  â”‚    Source: AE Data + Literature + Registry + Protocol                           â”‚   â”‚   â”‚
â”‚  â”‚  â”‚    Impact: Requires narrative in CSR; consider protocol amendment               â”‚   â”‚   â”‚
â”‚  â”‚  â”‚    Action: [View Signal Analysis] [Draft Amendment]                             â”‚   â”‚   â”‚
â”‚  â”‚  â”‚                                                                                  â”‚   â”‚   â”‚
â”‚  â”‚  â”‚ 3. ğŸŸ¡ AT-RISK PATIENTS: 7 patients overdue >60 days                             â”‚   â”‚   â”‚
â”‚  â”‚  â”‚    Source: Visit Data + Protocol windows                                         â”‚   â”‚   â”‚
â”‚  â”‚  â”‚    Impact: Potential loss to follow-up; power reduction if lost                 â”‚   â”‚   â”‚
â”‚  â”‚  â”‚    Action: [View Patient List] [Generate Outreach Plan]                         â”‚   â”‚   â”‚
â”‚  â”‚  â”‚                                                                                  â”‚   â”‚   â”‚
â”‚  â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜   â”‚   â”‚
â”‚  â”‚                                                                                          â”‚   â”‚
â”‚  â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”   â”‚   â”‚
â”‚  â”‚  â”‚ ğŸ“ˆ BENCHMARKING vs EXTERNAL SOURCES                                              â”‚   â”‚   â”‚
â”‚  â”‚  â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤   â”‚   â”‚
â”‚  â”‚  â”‚                                                                                  â”‚   â”‚   â”‚
â”‚  â”‚  â”‚ Metric            H-34      Literature     Registry      Status                 â”‚   â”‚   â”‚
â”‚  â”‚  â”‚ â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€ â”‚   â”‚   â”‚
â”‚  â”‚  â”‚ HHS Improvement   +34.9     +28 to +45     +32 median    âœ… Mid-range           â”‚   â”‚   â”‚
â”‚  â”‚  â”‚ MCID Rate         62%       60-80%         68% median    âœ… Within range        â”‚   â”‚   â”‚
â”‚  â”‚  â”‚ Revision Rate     8.1%      5-8%           6.2% median   âš ï¸ Upper boundary      â”‚   â”‚   â”‚
â”‚  â”‚  â”‚ AE Rate           35%       28-40%         35%           âœ… Expected            â”‚   â”‚   â”‚
â”‚  â”‚  â”‚ 2yr Survival      92%       90-96%         94%           âœ… Within CI           â”‚   â”‚   â”‚
â”‚  â”‚  â”‚                                                                                  â”‚   â”‚   â”‚
â”‚  â”‚  â”‚ Sources: Meding 2025, Vasios et al, Harris 2025, Dixon 2025, AOANJRR 2024       â”‚   â”‚   â”‚
â”‚  â”‚  â”‚                                                                                  â”‚   â”‚   â”‚
â”‚  â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜   â”‚   â”‚
â”‚  â”‚                                                                                          â”‚   â”‚
â”‚  â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”   â”‚   â”‚
â”‚  â”‚  â”‚ ğŸ“… REGULATORY TIMELINE                                                           â”‚   â”‚   â”‚
â”‚  â”‚  â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤   â”‚   â”‚
â”‚  â”‚  â”‚                                                                                  â”‚   â”‚   â”‚
â”‚  â”‚  â”‚ Today â”€â”€â”€â”€â”€â”€â—â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â–¶   â”‚   â”‚   â”‚
â”‚  â”‚  â”‚             â”‚                                                                    â”‚   â”‚   â”‚
â”‚  â”‚  â”‚      Q1 2026â”‚  Q2 2026      Q3 2026      Q4 2026      Q1 2027      Q2 2027     â”‚   â”‚   â”‚
â”‚  â”‚  â”‚             â”‚                                                                    â”‚   â”‚   â”‚
â”‚  â”‚  â”‚             â”œâ”€ n=15 eval â”€â”€â”€â”œâ”€ n=25 interim â”€â”€â”€â”œâ”€ n=35 â”€â”€â”€â”œâ”€ CSR draft â”€â”€â”€â”œâ”€ Submit â”‚   â”‚
â”‚  â”‚  â”‚                             â”‚ (Current target)                                   â”‚   â”‚   â”‚
â”‚  â”‚  â”‚                                                                                  â”‚   â”‚   â”‚
â”‚  â”‚  â”‚ Status: ON TRACK with 2-month buffer                                            â”‚   â”‚   â”‚
â”‚  â”‚  â”‚ Risk: Follow-up attrition could erode buffer                                    â”‚   â”‚   â”‚
â”‚  â”‚  â”‚                                                                                  â”‚   â”‚   â”‚
â”‚  â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜   â”‚   â”‚
â”‚  â”‚                                                                                          â”‚   â”‚
â”‚  â”‚  [Download Executive Summary PDF] [Schedule Review Meeting] [Drill Down to Details]     â”‚   â”‚
â”‚  â”‚  [Compare to Last Month] [Export for Board Presentation]                                â”‚   â”‚
â”‚  â”‚                                                                                          â”‚   â”‚
â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜   â”‚
â”‚                                                                                                  â”‚
â”‚  PROVENANCE: This dashboard aggregates 6 data sources automatically:                            â”‚
â”‚  Study Data (21 sheets), Protocol (CIP v2.0), Literature (15 PDFs), Registry (AOANJRR),        â”‚
â”‚  EC Documents (approval status), Prior Reports (Intermediate Report Dec 2023)                  â”‚
â”‚                                                                                                  â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

| Aspect | Why This Wins |
|--------|---------------|
| **Aggregated** | Single view synthesizes 6+ data sources into actionable summary |
| **Contextualized** | Every metric shown with literature/registry comparison |
| **Proactive** | Highlights issues requiring attention, not just data |
| **Executive-Ready** | One-click export for board presentations, regulatory meetings |

---

### Summary: Why These 5 Use Cases Win

| UC | Capability Demonstrated | Traditional Approach | Time Saved | Strategic Value |
|----|------------------------|---------------------|------------|-----------------|
| **UC1** | Multi-source regulatory readiness | 3-5 days manual assembly | 95% | Catch gaps before they cause delays |
| **UC2** | Cross-source safety contextualization | Weeks of literature review | 90% | Explain signals, avoid false alarms |
| **UC3** | Document-as-Code deviation detection | Hours per monitoring visit | 99% | Real-time compliance, not retrospective |
| **UC4** | ML + Literature risk stratification | Subjective clinical judgment | 80% | Focus resources on high-risk patients |
| **UC5** | Aggregated executive intelligence | Days of report preparation | 95% | Strategic decisions with full context |

**Combined Value Proposition:**

> These 5 use cases transform clinical study operations from **reactive data retrieval** to **proactive, contextualized, actionable intelligence**. Each use case demonstrates capabilities that CANNOT be achieved with traditional BI tools, simple chatbots, or RAG-only approaches. The platform doesn't just answer questionsâ€”it **anticipates needs, correlates sources, and drives decisions**.

---

# PART 2: HOW WE DO IT (Key Differentiators)

---

## Multi-Source Data Architecture

> **The Core Challenge:** Traditional BI systems query ONE data source at a time. Our platform performs **cross-source reasoning**â€”correlating structured study data with unstructured protocols, literature, and registry benchmarks to surface insights that NO SINGLE SOURCE can provide.

### Available Data Sources for H-34 POC

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚                         MULTI-SOURCE CLINICAL INTELLIGENCE ARCHITECTURE                          â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                                                                  â”‚
â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”   â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”   â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”    â”‚
â”‚  â”‚   ğŸ“Š STRUCTURED DATA     â”‚   â”‚   ğŸ“„ PROTOCOL DOCUMENTS   â”‚   â”‚   ğŸ“š LITERATURE PDFs     â”‚    â”‚
â”‚  â”‚   (H-34 Excel Export)    â”‚   â”‚   (RAG-indexed)          â”‚   â”‚   (RAG-indexed)          â”‚    â”‚
â”‚  â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤   â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤   â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤    â”‚
â”‚  â”‚ â€¢ Patient demographics   â”‚   â”‚ â€¢ CIP v2.0 (Nov 2024)    â”‚   â”‚ â€¢ Meding et al 2025      â”‚    â”‚
â”‚  â”‚ â€¢ HHS/OHS scores (5 pts) â”‚   â”‚ â€¢ Schedule of Assessmentsâ”‚   â”‚ â€¢ Dixon et al 2025       â”‚    â”‚
â”‚  â”‚ â€¢ Radiographic evals     â”‚   â”‚ â€¢ Endpoint definitions   â”‚   â”‚ â€¢ Vasios et al           â”‚    â”‚
â”‚  â”‚ â€¢ Adverse events         â”‚   â”‚ â€¢ Visit windows          â”‚   â”‚ â€¢ Zucchet et al 2025     â”‚    â”‚
â”‚  â”‚ â€¢ Revision/explants      â”‚   â”‚ â€¢ I/E criteria           â”‚   â”‚ â€¢ Harris et al 2025      â”‚    â”‚
â”‚  â”‚ â€¢ Batch/lot numbers      â”‚   â”‚ â€¢ AE definitions         â”‚   â”‚ â€¢ Willems et al 2025     â”‚    â”‚
â”‚  â”‚ â€¢ Surgery details        â”‚   â”‚ â€¢ Success criteria       â”‚   â”‚ â€¢ +10 more publications  â”‚    â”‚
â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜   â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜   â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜    â”‚
â”‚              â”‚                             â”‚                             â”‚                      â”‚
â”‚              â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜                      â”‚
â”‚                                            â–¼                                                    â”‚
â”‚                              â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”                                       â”‚
â”‚                              â”‚   ğŸ¤– AGENTIC AI LAYER    â”‚                                       â”‚
â”‚                              â”‚   (Cross-Source Reasoning)â”‚                                       â”‚
â”‚                              â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤                                       â”‚
â”‚                              â”‚ â€¢ Protocol Reasoning Agentâ”‚                                       â”‚
â”‚                              â”‚ â€¢ Data Quality Agent      â”‚                                       â”‚
â”‚                              â”‚ â€¢ Safety Signal Agent     â”‚                                       â”‚
â”‚                              â”‚ â€¢ Literature Context Agentâ”‚                                       â”‚
â”‚                              â”‚ â€¢ Narrative Evidence Agentâ”‚                                       â”‚
â”‚                              â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜                                       â”‚
â”‚                                            â”‚                                                    â”‚
â”‚              â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”                      â”‚
â”‚              â”‚                             â”‚                             â”‚                      â”‚
â”‚              â–¼                             â–¼                             â–¼                      â”‚
â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”   â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”   â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”    â”‚
â”‚  â”‚   ğŸ“ˆ REGISTRY DATA       â”‚   â”‚   ğŸ“‹ STUDY REPORTS       â”‚   â”‚   ğŸ“ TMF DOCUMENTS       â”‚    â”‚
â”‚  â”‚   (External Benchmarks)  â”‚   â”‚   (Intermediate Results) â”‚   â”‚   (Compliance Checks)    â”‚    â”‚
â”‚  â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤   â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤   â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤    â”‚
â”‚  â”‚ â€¢ AOANJRR: 5-8% rev@2yr  â”‚   â”‚ â€¢ H-34 Intermediate RPT  â”‚   â”‚ â€¢ EC approvals           â”‚    â”‚
â”‚  â”‚ â€¢ NJR: UK benchmark data â”‚   â”‚ â€¢ Progress reports       â”‚   â”‚ â€¢ Protocol deviations logâ”‚    â”‚
â”‚  â”‚ â€¢ EPRD: Germany data     â”‚   â”‚ â€¢ Safety summaries       â”‚   â”‚ â€¢ Training logs          â”‚    â”‚
â”‚  â”‚ â€¢ Published benchmarks   â”‚   â”‚ â€¢ Enrollment updates     â”‚   â”‚ â€¢ Monitoring visit logs  â”‚    â”‚
â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜   â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜   â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜    â”‚
â”‚                                                                                                  â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

### Why Multi-Source Matters: Single-Source vs Multi-Source Intelligence

| Question Type | Single-Source Answer | Multi-Source Agentic Answer |
|---------------|---------------------|----------------------------|
| "What's our revision rate?" | "8.1% (3/37 patients)" | "8.1% (3/37). **Context:** AOANJRR reports 5-8% for revision THA at 2yr. Our rate is at upper boundary. **Literature:** Meding et al (2025) reports 6.2% for similar cementless cups. **Protocol insight:** All 4 events occurred <90 days, suggesting early mechanical failures rather than long-term wearâ€”different risk profile than registry patterns." |
| "Are outcomes acceptable?" | "Mean HHS +34.9 points" | "Mean HHS improvement +34.9 pts (n=8). **Protocol compliance:** Exceeds 20-point MCID threshold defined in CIP Section 8.2. **Literature context:** Vasios et al reports 28-42 pt improvement range; our results are mid-range. **Registry benchmark:** AOANJRR shows 85% report 'good/excellent' outcomes; our 62% MCID achievement suggests monitoring needed for non-responders." |
| "Any safety concerns?" | "15 AEs, 12 SAEs" | "15 AEs in 13 patients (35%). **Protocol compliance:** All SAEs reported within 24-hour window per CIP Section 9.1. **Literature comparison:** Harris et al (2025) reports 28-40% AE rate for revision THA; we're within range. **Cross-domain signal:** 3/5 periprosthetic fractures occurred in patients with osteoporosis diagnosisâ€”matches risk pattern in Dixon et al. **Registry context:** AOANJRR flags fracture rates >10% as concerning; our 13% warrants enhanced bone quality assessment protocol." |

---

## Document-as-Code: Protocol Digitization & Beyond

> **The Critical Distinction:** RAG retrieval answers "what does the document say?" Document-as-Code answers "what does this mean for my data, and what should I do?" It transforms static PDFs into **executable knowledge models** that drive automated validation, compliance checking, and intelligent automation.

### RAG Retrieval vs Document-as-Code

| Aspect | RAG Retrieval (Standard) | Document-as-Code (Differentiator) |
|--------|--------------------------|-----------------------------------|
| **What it does** | Finds relevant text passages | Extracts structured rules and executes them |
| **Output** | "Section 6.2 says visits should occur at 2mo, 6mo, 1yr, 2yr" | `{"visit_2mo": {"window_days": [-14, 28], "required_forms": ["HHS", "OHS", "Radiology"]}}` |
| **Automation** | Human reads and interprets | System automatically validates data against rules |
| **Compliance** | "The protocol requires X" (informational) | "Patient 15 is OUT OF WINDOW by 8 days" (actionable) |
| **Scalability** | Each query re-searches document | Rules extracted once, applied to all patients instantly |

### Document Digitization Schemas

#### Protocol-as-Code (CIP_H-34_v.2.0)

```yaml
# PROTOCOL DIGITIZATION SCHEMA
protocol:
  id: "H-34"
  version: "2.0"
  title: "DELTA Revision Cup Clinical Investigation"

# SCHEDULE OF ASSESSMENTS â†’ Executable Visit Model
schedule_of_assessments:
  visits:
    - id: "fu_2mo"
      day_offset: 60
      window: [-14, +28]
      required_assessments: ["hhs", "ohs", "radiology", "ae_review"]
    - id: "fu_6mo"
      day_offset: 180
      window: [-30, +30]
      required_assessments: ["hhs", "ohs", "radiology", "ae_review"]
    - id: "fu_1yr"
      day_offset: 365
      window: [-30, +60]
      required_assessments: ["hhs", "ohs", "radiology", "ae_review"]
    - id: "fu_2yr"
      day_offset: 730
      window: [-60, +60]
      required_assessments: ["hhs", "ohs", "radiology", "ae_review"]
      critical: true  # Primary endpoint collection

# ENDPOINT DEFINITIONS â†’ Executable Calculations
endpoints:
  primary:
    id: "hhs_improvement"
    calculation: "hhs_2yr - hhs_baseline"
    success_threshold: 20  # MCID
    success_criterion: "improvement >= 20 points"

# SAFETY THRESHOLDS â†’ Automated Monitoring Triggers
safety_thresholds:
  revision_rate_concern: 0.10  # 10% triggers review
  sae_rate_concern: 0.40       # 40% triggers review
  fracture_rate_concern: 0.08  # 8% triggers bone quality review
```

#### Literature-as-Code (Benchmark Extraction)

```yaml
# LITERATURE DIGITIZATION SCHEMA
publication:
  id: "meding_2025"
  title: "Long-term outcomes of cementless revision THA"

benchmarks:
  outcomes:
    hhs_improvement:
      mean: 38.2
      sd: 14.3
      ci_95: [35.7, 40.7]
    revision_rate:
      value: 0.062  # 6.2%
      ci_95: [0.041, 0.089]
    mcid_achievement:
      value: 0.72  # 72%
```

#### Registry-as-Code (External Validation)

```yaml
# REGISTRY DIGITIZATION SCHEMA
registry:
  id: "aoanjrr_2024"
  name: "Australian Orthopaedic Association National Joint Replacement Registry"

benchmarks:
  revision_tha:
    cementless_cup:
      survival_2yr: 0.94  # 94%
      revision_rate_median: 0.062
      revision_rate_p95: 0.12

risk_factors:
  osteoporosis:
    revision_hr: 1.8
    fracture_hr: 2.4
  bmi_over_35:
    revision_hr: 1.6
```

### Use Cases ONLY Possible with Document-as-Code

| # | Use Case | Why RAG Can't Do This |
|---|----------|----------------------|
| **DC1** | **Automated Visit Window Validation** | RAG returns text "visits should occur within Â±30 days"; cannot calculate dates |
| **DC2** | **Real-time Eligibility Re-verification** | RAG can quote I/E criteria text; cannot evaluate patient data |
| **DC3** | **Endpoint Calculation with Protocol-Defined Rules** | RAG describes endpoint; cannot compute |
| **DC4** | **Automated eCRF Edit Check Generation** | RAG can describe requirements; cannot create executable checks |
| **DC5** | **Protocol-Driven Chase List Generation** | RAG states what's required; cannot identify what's missing |
| **DC6** | **Literature-Grounded Outlier Detection** | RAG quotes literature ranges; cannot apply to your data |
| **DC7** | **Registry-Based Risk Stratification** | RAG returns registry statistics; cannot score patients |
| **DC8** | **Automated Deviation Classification** | RAG describes deviation categories; cannot classify |
| **DC9** | **Dynamic Success Criteria Monitoring** | RAG states success criteria; cannot track progress |
| **DC10** | **Cross-Document Rule Conflict Detection** | RAG retrieves independently; cannot compare rules |

---

# PART 3: SUPPORTING TECHNICAL DETAIL

---

## Data Foundation & Constraints

### H-34 Study Data Inventory

| Sheet | Content | Records | Key Fields |
|-------|---------|---------|------------|
| 1 Patients | Demographics | 37 | Age, Gender, BMI, Status |
| 2 Preoperatives | Diagnosis, history | 36 | Primary diagnosis, prior surgeries |
| 3 Radiographical (Preop) | Baseline imaging | 36 | Bone quality, defects |
| 4 Intraoperatives | Surgery details | 36 | Cup/stem type, size, cement |
| 5 Surgery Data | Procedure info | 35 | Approach, duration, complications |
| 6 Batch Numbers | Lot tracking | 33 | 26 unique batch numbers |
| 7-16 Follow-ups | Visit data + Radiology | Varies | By timepoint |
| 17 Adverse Events | Safety events | 15 | 13 patients, 12 SAEs |
| 18 Score HHS | Primary endpoint | 112 | Across 5 timepoints |
| 19 Score OHS | Secondary endpoint | 112 | Across 5 timepoints |
| 20 Explants | Revisions | 4 | 3 unique patients |
| 21 Reimplants | Revision surgery | 3 | Revision implant details |

### Critical Sample Size Constraints

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ DATA AVAILABILITY BY TIMEPOINT                                              â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                                              â”‚
â”‚  HHS Scores:                                                                â”‚
â”‚                                                                              â”‚
â”‚  Preoperative   â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆ  36 patients           â”‚
â”‚  2 Months       â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆ         29 patients           â”‚
â”‚  6 Months       â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆ              24 patients           â”‚
â”‚  1 Year         â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆ                       15 patients           â”‚
â”‚  2 Years        â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆ                               8 patients  âš ï¸        â”‚
â”‚                                                                              â”‚
â”‚  Patients with 3+ timepoints: 23                                            â”‚
â”‚  Patients with all 5 timepoints: 8                                          â”‚
â”‚                                                                              â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ EVENT COUNTS (For Statistical Modeling)                                     â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                                              â”‚
â”‚  Revisions/Explants:  4 events (3 patients)  âŒ Insufficient for modeling   â”‚
â”‚  Adverse Events:      15 events (13 patients) âš ï¸ Limited for pattern detect â”‚
â”‚  SAEs:                12 events               âš ï¸ Descriptive only           â”‚
â”‚                                                                              â”‚
â”‚  Minimum for Cox PH regression: ~10 events per covariate                    â”‚
â”‚  Minimum for ML classification: ~50+ events                                 â”‚
â”‚  Current revision events: 4  â†’ INSUFFICIENT                                 â”‚
â”‚                                                                              â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

### Capability Feasibility Matrix

**With Real Data Only (37 patients):**

| Capability | Status | Constraint |
|------------|--------|------------|
| Cox PH risk factors | âŒ NOT FEASIBLE | 4 events, need 10+ per covariate |
| ML risk prediction | âŒ NOT FEASIBLE | 4 events cannot train a model |
| Trajectory clustering | âš ï¸ MARGINAL | Only 8 patients with 5 timepoints |
| Descriptive statistics | âœ… FEASIBLE | Full dataset available |
| Literature comparison | âœ… FEASIBLE | External data available |

**With Synthetic Data Augmentation (737 total: 37 real + 700 synthetic):**

| Capability | Status | Data Available |
|------------|--------|----------------|
| Cox PH risk factors | âœ… FEASIBLE | 60 revision events |
| ML risk prediction | âœ… FEASIBLE | 60 events for training/validation |
| Trajectory clustering | âœ… FEASIBLE | 102 patients with complete trajectories |
| 2-Year outcome forecasting | âœ… FEASIBLE | 277 patients with 2-year outcomes |

> **Transparency:** Synthetic data is generated from real H-34 distributions + published literature benchmarks. All synthetic records marked with `is_synthetic=True`.

---

## Validated Capability Matrix

### REACTIVE: Agentic Question-Answering

| Tier | Question Type | Example | Data Sources |
|------|---------------|---------|--------------|
| **TIER 0** | Multi-Source Intelligence | "How do we compare to published literature and registry benchmarks?" | Protocol + Study + Literature + Registry |
| **TIER 1** | Cross-Domain Clinical | "Are we on track to meet the primary endpoint?" | Study data + Literature benchmarks |
| **TIER 2** | Protocol-Aware Management | "What protocol deviations might exist?" | Protocol rules + Visit data |
| **TIER 3** | Safety Signal Intelligence | "Analyze AEs and identify clustering patterns" | AE data + Demographics + Radiology |
| **TIER 4** | Data Quality | "Generate data quality report" | All study data sheets |

### PROACTIVE: Intelligent Surveillance

| Tier | Alert Type | Example | Sources Monitored |
|------|------------|---------|-------------------|
| **TIER 0** | Multi-Source Autonomous | Protocol-Literature Divergence Alert | Study + Protocol + Literature + Registry |
| **TIER 1** | Cross-Domain Safety | Outcome-Radiographic Discordance | HHS scores + Radiology |
| **TIER 2** | Study Execution | Endpoint Evaluability at Risk | Visit completion + Protocol windows |
| **TIER 3** | Predictive Early Warning | Elevated Revision Risk Identified | ML model + Clinical data |

### PREDICTIVE: ML/Analytics Capabilities

| Capability | Business Question | Technology | Data Required |
|------------|-------------------|------------|---------------|
| Enrollment Forecasting | "When will we reach target?" | Prophet | Real data (36 surgeries) |
| Survival Analysis | "What is implant survival?" | Kaplan-Meier | Real data (descriptive) |
| Risk Prediction | "Which patients need monitoring?" | XGBoost | Synthetic data (60 events) |
| Trajectory Classification | "What recovery pattern?" | K-Means | Synthetic data (102 complete) |

---

## Technology Stack

| Component | Technology | Purpose |
|-----------|------------|---------|
| **LLM** | Gemini 2.5 Pro | Natural language understanding, response generation |
| **RAG** | ChromaDB + text-embedding-004 | Document retrieval (protocol, literature) |
| **Time Series** | Prophet | Enrollment forecasting |
| **Survival** | lifelines | Kaplan-Meier curves |
| **ML** | XGBoost, scikit-learn | Risk prediction, clustering |
| **Backend** | FastAPI | API layer |
| **Frontend** | Streamlit | Demo interface |

---

## RFP Alignment

### High-Priority Use Cases â€” Direct Coverage

| Client Requirement | Our Capability | POC Demonstration |
|--------------------|----------------|-------------------|
| Manage, interpret, organize large data volumes | Multi-source data fusion | Cross-domain queries across 21 sheets |
| Identify trends, correlations, outliers | Anomaly detection, trajectory analysis | Discordance detection, AE clustering |
| Generate automated reports | Templated report generation with provenance | Query-to-insight with traceability |
| Provide clinical insights via chatbot | Natural language Q&A with provenance | All REACTIVE questions |
| Stratify/analyze clinical study data | Subgroup analysis, risk stratification | Individual risk scoring |

### Agentic AI Differentiation â€” What Traditional BI Cannot Do

| Capability | Traditional BI | Our Agentic AI Platform |
|------------|----------------|------------------------|
| **Cross-domain reasoning** | Manual joins, separate queries | Single question spans outcomes + radiology + safety |
| **Literature-grounded context** | Not available | Automatic comparison to published benchmarks |
| **Natural language** | Requires SQL/query building | Ask in plain English, get cited answers |
| **Predictive intelligence** | Static thresholds | ML-based risk scoring with uncertainty |
| **Proactive surveillance** | Scheduled reports only | Autonomous pattern detection with alerts |
| **Protocol awareness** | Manual compliance checks | Document-as-Code executes rules automatically |
| **Actionable recommendations** | Data only | "Do this next" with clinical rationale |

### POC Scope Coverage

| RFP Category | Total Prompts | Covered by POC | Coverage |
|--------------|---------------|----------------|----------|
| Data Management | 12 | 11 | 92% |
| Statistical Analysis | 8 | 8 | 100% |
| Data Interpretation | 4 | 4 | 100% |
| Study Management | 11 | 8 | 73% |
| Information/Strategy | 3 | 2 | 67% |
| Regulatory | 2 | 1 | 50% |
| **TOTAL** | **40** | **34** | **85%** |

---

## Success Criteria

| Criterion | Target | Measurement |
|-----------|--------|-------------|
| Q&A accuracy (deterministic) | 100% | Exact match to source data |
| Q&A accuracy (LLM synthesis) | >90% | Expert review |
| Response time | <10 seconds | Timing |
| Provenance completeness | 100% | Every answer cites source |
| Honest uncertainty | 100% | System never overstates confidence |

---

*Version 9.0 â€” POC Demonstration-Ready Agentic Intelligence Platform*

**Document Structure (v9.0):**
- **PART 1: What We Will Demonstrate** â€” TOP 5 POC Use Cases (UC1-UC5) showcasing multi-source reasoning, Document-as-Code, and actionable intelligence
- **PART 2: How We Do It** â€” Key differentiators (Multi-Source Architecture, Document-as-Code)
- **PART 3: Supporting Technical Detail** â€” Data constraints, capability matrix, technology stack, RFP alignment

**Version History:**
- v9.0: Restructured for impact â€” Use cases to top, supporting detail to bottom
- v8.0: Added TOP 5 POC USE CASES (UC1-UC5)
- v7.0: Added Document-as-Code digitization schemas
- v6.0: Added Multi-Source Architecture and TIER 0 capabilities

**Document Digitization Targets:**
- `protocol_rules.yaml` â€” CIP v2.0 (visit windows, endpoints, eligibility, safety thresholds)
- `literature_benchmarks.yaml` â€” 15 publications (outcome benchmarks, risk factors)
- `registry_norms.yaml` â€” AOANJRR/NJR (survival curves, percentiles, HRs)

*Real data: H-34DELTARevisionstudy_export_20250912.xlsx (N=37)*
*Synthetic data: H-34_SYNTHETIC_PRODUCTION.xlsx (N=700)*
*Unstructured sources: 15 Literature PDFs, Protocol v2.0, Registry reports, EC documents*
*Data audit date: January 11, 2026*
